Cutler Group LP Exelixis, Inc. Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$14.96 - $17.39 $35,904 - $41,736	2,400 New	2,400 $38,000
Q2 2020 Jul 22, 2020	SELL	$16.46 - $27.42 $17,595 - $29,311	-1,069 Closed	0 $0
Q1 2020 May 07, 2020	SELL	$14.46 - $21.8 $14,460 - $21,800	-1,000 Reduced 48.33%	1,069 $18,000
Q4 2019 Feb 06, 2020	SELL	$15.15 - $18.89 $33,390 - $41,633	-2,204 Reduced 51.58%	2,069 $36,000
Q3 2019 Oct 28, 2019	SELL	$17.68 - $22.65 $90,168 - $115,515	-5,100 Reduced 54.41%	4,273 $75,000
Q2 2019 Aug 09, 2019	BUY	$18.93 - $24.75 $54,291 - $70,983	2,868 Added 44.09%	9,373 $200,000
Q1 2019 May 10, 2019	BUY	$19.6 - $24.76 $118,188 - $149,302	6,030 Added 1269.47%	6,505 $154,000
Q4 2018 Feb 05, 2019	SELL	$13.65 - $21.8 $80,876 - $129,165	-5,925 Reduced 92.58%	475 $9,000
Q3 2018 Nov 07, 2018	BUY	$15.87 - $22.4 $2,380 - $3,360	150 Added 2.4%	6,400 $113,000
Q2 2018 Aug 10, 2018	SELL	$18.56 - $22.45 $242,115 - $292,860	-13,045 Reduced 67.61%	6,250 $134,000
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $20,067 - $28,892	906 Added 4.93%	19,295 $427,000
Q4 2017 Jan 17, 2018	SELL	$24.23 - $30.93 $122,482 - $156,351	-5,055 Reduced 21.56%	18,389 $559,000
Q3 2017 Oct 17, 2017	BUY	$23.35 - $29.24 $547,417 - $685,502	23,444	23,444 $568,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.